Trastuzumab for HER2-positive gastric and gastroesophageal junction cancers

Affiliations

¹ Department of Pathology, University of Texas Southwestern Medical Center and Children's Medical Center, 1935 Medical District Drive, Dallas, TX 75235, USA. jaspar@childrens.com

Comment

Jason Park. Biomark Med. 2010 Dec.

. 2010 Dec;4(6):793.

¹ Department of Pathology, University of Texas Southwestern Medical Center and Children's Medical Center, 1935 Medical District Drive, Dallas, TX 75235, USA. jaspar@childrens.com

No abstract available

Comment on

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Bang YJ, et al. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.